The estimated Net Worth of Louis J. Aronne is at least $22.4 mil dollars as of 4 September 2015. Louis Aronne owns over 5,000 units of MYOS RENS Technology stock worth over $22,422 and over the last 12 years he sold MYOS stock worth over $0. In addition, he makes $0 as Independent Director at MYOS RENS Technology.
Sign up
Louis Aronne MYOS stock SEC Form 4 insiders trading
Louis has made over 2 trades of the MYOS RENS Technology stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of MYOS stock worth $8,800 on 4 September 2015.
The largest trade he's ever made was buying 160,000 units of MYOS RENS Technology stock on 6 July 2012 worth over $40,000. On average, Louis trades about 18,333 units every 128 days since 2012. As of 4 September 2015 he still owns at least 22,200 units of MYOS RENS Technology stock.
You can see the complete history of Louis Aronne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Louis Aronne biography
Dr. Louis J. Aronne serves as Independent Director of the Company. Dr. Aronne is the Weill Professor of Metabolic Research and Director of the Comprehensive Weight Control Center which he founded in 1986 at Weill Cornell Medical College. He is the former Chairman of the American Board of Obesity Medicine and an Adjunct Clinical Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Aronne is former president of the Obesity Society and a fellow of the American College of Physicians. He has been an investigator on more than 40 trials, authored more than 100 papers and book chapters on obesity and edited the National Institutes of Health Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Dr. Aronne has won several awards for teaching, including the Leo M. Davidoff Society Prize from Albert Einstein College of Medicine in 1983 and Eliot Hochstein Teaching Award from Cornell University in 1990. Dr. Aronne graduated Phi Beta Kappa from Trinity College with a BS in biochemistry and from Johns Hopkins University School of Medicine. Aronne’s skills as a physician and his knowledge and experience with respect to obesity and related metabolic diseases qualifies him to serve on our Board of Directors.
How old is Louis Aronne?
Louis Aronne is 64, he's been the Independent Director of MYOS RENS Technology since 2014. There are 1 older and 6 younger executives at MYOS RENS Technology. The oldest executive at MYOS RENS Technology, Inc. is Christopher Dewey, 75, who is the Independent Director.
What's Louis Aronne's mailing address?
Louis's mailing address filed with the SEC is C/O MYOS RENS TECHNOLOGY INC., 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS, NJ, 07927.
Insiders trading at MYOS RENS Technology
Over the last 12 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 2,115,845 units worth $2,654,259 . The most active insiders traders include David J Matlin, Christopher Pechock, eJoseph Mannello. On average, MYOS RENS Technology executives and independent directors trade stock every 78 days with the average trade being worth of $59,361. The most recent stock trade was executed by Joseph Mannello on 31 March 2020, trading 16,529 units of MYOS stock currently worth $16,694.
What does MYOS RENS Technology do?
MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.
What does MYOS RENS Technology's logo look like?
Complete history of Louis Aronne stock trades at MYOS RENS Technology
MYOS RENS Technology executives and stock owners
MYOS RENS Technology executives and other stock owners filed with the SEC include:
-
Joseph Mannello,
Chief Executive Officer, Director -
Robert Hariri,
Independent Chairman of the Board -
Eric Zaltas,
Independent Director -
Andrew Ponte,
Independent Director -
Christopher Pechock,
Independent Director -
Victor Mandel,
Independent Director -
Christopher Dewey,
Independent Director -
Louis Aronne,
Independent Director -
Ren Ren,
Director -
Sapna Srivastava,
Director -
Joseph Dos Santos,
Chief Financial Officer -
Kenrick Bryce Toussaint,
Chief Executive Officer -
Buzz Aldrin,
Director -
Zhengguang Lyu,
Director -
Robert C. Jr. Ashton,
Chief Medical Officer -
Peter Diamandis,
Director -
John Craig Venter,
Director -
Peter Levy,
COO & Executive VP -
John Nosta,
Director -
Carl De Freitas,
Interim CFO -
Glen R. Fleischer,
Chief Executive Officer -
David J Matlin,
10% owner